Funding Opportunity PAR-24-049 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

Notice NOT-OD-24-025 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-006 from the NIH Guide for Grants and Contracts

Notice NOT-OD-24-018 from the NIH Guide for Grants and Contracts

Notice NOT-PM-24-001 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-028 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits applications for one or more Data Coordinating Centers (DCCs) to support BRAIN CONNECTS, a networked consortium of Comprehensive Centers and Specialized Projects funded under RFA-NS-22-047, RFA-NS-22-048, and RFA-NS-22-049. The goals of these awards are to develop the research capacity and technical capabilities for comprehensive brain-wide connectivity mapping in mouse, human, and non-human primate (NHP). BRAIN CONNECTS projects will collect and process unprecedented volumes of anatomical data by scaling up cutting-edge acquisition modalities and analysis methods, to demonstrate the feasibility of collecting, reconstructing, analyzing, integrating, disseminating, and interpreting connectivity maps from entire brains. The resulting feasibility data from these awards are expected to inform NIH decisions on program continuation in a potential subsequent five-year funding period for production of brain-wide wiring diagrams. NIH expects to fund one or more BRAIN CONNECTS DCCs, which will collaborate with CONNECTS data generating projects to (1) coordinate activities of the BRAIN CONNECTS Network, (2) develop and harmonize common data processing pipelines, (3) integrate and disseminate data analytic tools and capabilities, (4) establish a unified knowledge base for connectivity data of diverse modalities, and (5) organize and implement outreach and engagement to the wider research community and the general public. Awards will be integrated into the BRAIN CONNECTS Network as a coordinated effort aimed at developing the ability to generate wiring diagrams spanning entire brains across multiple scales and species.

Notice NOT-TR-24-003 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-004 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-005 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-006 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-25-008 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity announcement (NOFO) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization. This NOFO aims to position innovative and validated methods for future clinical development.

Notice NOT-NR-24-001 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-075 from the NIH Guide for Grants and Contracts

Notice NOT-DE-24-006 from the NIH Guide for Grants and Contracts

Notice NOT-MD-23-021 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-069 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-043 from the NIH Guide for Grants and Contracts. Through this non-competitive single source cooperative agreement Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits an application from (-----institute name-----) with the intent of funding a single award to continue to support the AIDS and Cancer Specimen Resource (ACSR). This is a reissue of RFA-CA-18-012. The ACSRs mission is to address the specimen needs of clinician and basic researchers in HIV and HIV-associated malignancy research. The ACSR is an international repository with specimens that reflect different eras of the epidemic (notably pre-cART and post-cART), different regions of the world, and people of diverse genetic backgrounds with different environmental exposures. Specimens have been obtained from people with HIV (PWH), people at risk for acquiring HIV, and HIV-uninfected controls. Specimens have been obtained from participants in clinical trials, observational cohort studies, or other research studies conducted by HIV investigators and consortium. The ACSR uses informed approaches to prospectively curate specimens in the USA, sub-Saharan Africa and Latin America that will be most valuable for the research community. Specimens and associated data are made available to the research community-at-large at NO COST. A second key role of the ACSR, is to serve as the AMC Biorepository for the AIDS Malignancy Consortium (AMC). The AMC is an NCI funded, multicenter clinical trials cooperative group that performs clinical trials research in the treatment and prevention of HIV-associated malignancies. The ACSR is currently providing support for domestic (two), sub-Saharan African, and Latin American biorepositories for the AMC.

Funding Opportunity PAR-24-043 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Notice NOT-HL-23-116 from the NIH Guide for Grants and Contracts

Notice NOT-HS-24-003 from the NIH Guide for Grants and Contracts